Fact Source: Financial Supervisory Service DART / 2025-03-14
Disclosure Type: Results of Annual General Meeting of Shareholders
💡 3-Second Summary
SAMSUNG BIOLOGICS finalized its FY2024 financial performance at its 14th Annual General Meeting, while shaking up its governance architecture by electing former Samsung Electronics financial expert Yoo Seung-ho as Internal Director and former Presidential Policy Chief Lee Ho-seung as Independent Director.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Approval of Financial Statements (14th Fiscal Year / FY2024, Unit: KRW):
- Consolidated: Revenue KRW 4,547,322,000,000 (KRW 4.547T), Operating Profit KRW 1,320,052,000,000 (KRW 1.320T), Net Income KRW 1,083,316,000,000 (KRW 1.083T) / Earnings Per Share (EPS) KRW 15,221
- Separate (Standalone): Revenue KRW 3,497,146,000,000 (KRW 3.497T), Operating Profit KRW 1,321,426,000,000 (KRW 1.321T), Net Income KRW 1,050,967,000,000 (KRW 1.051T) / Earnings Per Share (EPS) KRW 14,766
- External Auditor’s Opinion: ‘Unmodified (Clean)’ for both consolidated and separate statements.
- Dividend Status: No cash, property, or stock dividends were declared or approved for this fiscal period (-) [Dividend amount and yield are not applicable].
- Election of Directors & Audit Committee Members (3-year terms each):
- Yoo Seung-ho (Newly Elected Internal Director): Current Head of Management Support Center (VP / CFO) at SAMSUNG BIOLOGICS.
- Lee Ho-seung (Newly Elected Independent Director): Former Chief of Staff to the President for Policy / Former 1st Vice Minister of Economy and Finance.
- Lee Chang-woo (Re-elected Independent Director): Professor Emeritus at Seoul National University Graduate School of Business (serving as Chairman of the Audit Committee).
- Lee Ho-seung (Newly Elected Audit Committee Member): Cross-appointed as a member of the Audit Committee.
- Board of Directors Structure: Following the AGM, the board maintains 7 total directors, including 4 independent directors (representing a 57.14% ratio). The Audit Committee is composed entirely of 3 independent directors.
- Other Approved Agendas: Amendments to the Articles of Incorporation and the approval of the director remuneration limit were passed originally as proposed.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This AGM disclosure represents the final statutory sign-off on SAMSUNG BIOLOGICS’ record-breaking FY2024 operating metrics, while formalizing a structural refresh of its boardroom leadership. Securing an ‘Unmodified’ auditing opinion on a KRW 1.32T operating profit lines confirms the high data integrity of the firm’s balance sheet and reinforces its core fundamental.
From a structural standpoint, the election of the new board members yields important insights into future execution strategies. Internal Director Yoo Seung-ho, an expert in corporate financial management from his tenure at Samsung Electronics’ global operations, is expected to optimize capital allocation during large-scale CAPEX expansions and facility rollouts. On the other hand, Independent Director Lee Ho-seung, a career technocrat who served as Vice Minister of Economy and Finance, introduces heavy macroeconomic and geopolitical regulatory experience. His macro background could act as a potent buffer for managing international supply-chain blockades and navigating global compliance mandates, such as the U.S. Biosecure Act.
While the zero-dividend payout resolution despite achieving a solid KRW 15,221 EPS might disappoint income-seeking retail investors, it strongly highlights the company’s capital redeployment blueprint. Retaining retained earnings to fund multi-billion-dollar plant fabrications and next-generation therapeutic modalities signals a continued commitment to aggressive growth over near-term payouts. Preserving an independent director majority (57.14%) alongside an all-independent Audit Committee satisfies stringent ESG compliance parameters demanded by international institutional funds, thereby supporting steady inflows.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS’ 14th shareholder meeting clearly spelled out its operational strategy: strengthening institutional expertise and solidifying corporate governance. The weight carried by the newly appointed directors is considerable. Yoo Seung-ho, a veteran financial mind from Samsung Electronics, enters the inner circle to supervise internal spending, while Lee Ho-seung, a master corporate policy strategist, brings public sector foresight. This structural mix is intentionally engineered to mitigate execution risks across massive plant expansions while maneuvering through delicate international trade friction.
The decision to retain all profits instead of issuing dividends reaffirms their classic high-growth growth stock playbook. Management is signaling that utilizing cash to scale out capacity and capture dominant market share yields greater long-term value than minor cash distributions. With the historic FY2024 performance officially archived and the new leadership grid locked in, institutional eyes will now shift directly toward upcoming utilization metrics and new contract backlogs.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
